Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

226.60 +15.49 (+7.34%)

Streaming Delayed Price Updated: 10:25 AM EDT, Sep 11, 2026 Add to My Watchlist

Price and Volume

Volume	315,584
Open	212.71
Bid (Size)	226.18 (100)
Ask (Size)	226.96 (100)
Prev. Close	211.11
Today's Range	212.44 - 229.62
52wk Range	112.90 - 260.19
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+26.8%	+26.8%
1 Month	+5.0%	+5.0%
3 Month	-10.7%	-10.7%
6 Month	+47.0%	+47.0%
1 Year	+82.6%	+82.6%

More News

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

August 31, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Via The Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗

August 23, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗

August 17, 2026

Via Benzinga

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗

August 13, 2026

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗

August 11, 2026

Via Benzinga

Axsome Therapeutics Q2 Earnings Call Highlights ↗

August 10, 2026

Via MarketBeat

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 10, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗

August 04, 2026

Via The Motley Fool

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

July 14, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

Via The Motley Fool

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

July 07, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

Via The Motley Fool

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. ↗

July 02, 2026

Via The Motley Fool

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

June 26, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

June 18, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

Via The Motley Fool

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

June 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline ↗

June 06, 2026

Via MarketBeat

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

June 04, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

June 03, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 226.60

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 09/11/26 10:25 AM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 10.69B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.